ClinicalTrials.gg
CompletedNCT05267600BALLADUpdated Oct 23, 2025Results posted

A Phase 2/3 Study of Efgartigimod PH20 SC in Adult Participants With Bullous Pemphigoid

A Phase 2/3 interventional study of efgartigimod PH20 SC and placebo in Bullous Pemphigoid, sponsored by argenx. Completed at 129 sites in 21 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2025-10-23.

Sponsored by argenx · Phase 2/3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2/3
Study type
Interventional
Enrollment
98
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 15 studies in Pemphigoid, Bullous with a site in United States — 2 open to participants now, 2 under way, none of them phase 3. Pemphigoid, Bullous · United States.

Enrollment
3rd of 13
98 · median 11
Started
2022
with 1 other
Phase 2/3
2 of 15
none open now
Registered
13th of 15
by date
Lead sponsor
2 of 15
argenx

Among the 15 studies in Pemphigoid, Bullous with a site in United States, this one is the 3rd largest by enrollment of the 13 interventional ones that give a count, is one of 2 that started in 2022, is one of 2 in phase 2/3, and was the 13th registered.

Pemphigoid, Bullous

64 studies on the registry are indexed under Pemphigoid, Bullous; 8 are open to participants now.

Browse Pemphigoid, Bullous studies →

Open to participants now

2 of the 15 studies in Pemphigoid, Bullous with a site in United States are open now. Recruiting first, the newest first:

All 2 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 5 Pemphigoid, Bullous studies recruiting now, 3 set no upper age limit and none stop at 75 or younger; 1 takes children under 18; none take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 15 studies in Pemphigoid, Bullous with a site in United States, or all of them as a file.
02

Study summary

ARGX-113-2009 is an operationally seamless 2-part, phase 2/3, prospective, global, multicenter, randomized, double-blinded, placebo-controlled study to investigate the efficacy, safety, tolerability, immunogenicity, participant-reported outcome measures (including those assessing participant QoL), PK, and PD of efgartigimod PH20 SC administered via subcutaneous (SC) injection in adult participants with moderate to severe BP. This study intends to demonstrate that efgartigimod is an effective and safe treatment for BP, providing participants with control of disease activity (CDA) and eventually remission while reducing their cumulative exposure to OCS.

study will consist of 2 parts:

  • Part A of the study is a phase 2 evaluation that intends to provide proof of concept for the therapeutic activity of efgartigimod PH20 SC in participants with BP.
  • Part B of the study is a phase 3 evaluation that intends to confirm the results obtained from part A in a separate, larger group of participants with BP.

An interim analysis will be performed during part A (on data obtained through week 26 for all Part A participants) to assess the primary endpoint and several secondary endpoints, confirm the appropriate sample size for part B of the study, and determine whether the efficacy results observed through week 26 of part A warrant continued study of efgartigimod PH20 SC for the treatment of participants with BP (futility analysis).

03

Conditions studied

  • Bullous Pemphigoid

Browse trials for

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • The participant is willing and able to do the following:

    1. understand the requirements of the study
    2. provide written
    3. comply with the study protocol procedures.
  • The participant is male or female and has reached the age of consent at the time of signing the informed consent form (ICF).
  • Participants have clinical signs of BP.
  • use should be consistent with local regulations regarding the methods of contraception for those participating in clinical studies and: Women of must have a negative serum pregnancy test at screening and a negative urine pregnancy test at baseline before study intervention can be administered.

The full list of inclusion criteria can be found in the protocol.

Exclusion criteria

Exclusion Criteria:

  • Other forms of pemphigoid or other bullous diseases (AIBDs).
  • Received unstable dose of treatments known to cause or exacerbate BP for at least 4 weeks prior to the baseline visit
  • Use of BP treatments other than oral (OCS), topical corticosteroids (TCS), conventional or dapsone.
  • Known to OCS therapy
  • Active, chronic or latent infection at screening
  • Positive COVID-19 test result at screening (testing performed if required per local regulations).
  • History of unless deemed cured by adequate treatment with no evidence of recurrence for ≥3 years before the first administration of the IMP. Participants with the following cancers can be included at any time, provided they are adequately treated prior to their participation in the study: Basal cell or squamous cell skin cancer, Carcinoma in situ of the cervix, Carcinoma in situ of the breast, Incidental histological finding of prostate cancer
  • Clinical evidence of other significant serious diseases, have had a recent surgery, or who have any other condition that, in the opinion of the investigator, could confound the results of the study or put the patient at undue risk or prevent participants from complying with protocol requirements
  • Use of an product within 3 months before the first dose of IMP
  • Previously participated in a clinical study with efgartigimod or currently participating in another interventional clinical study
  • Known to any of the components of the administered treatments
  • Positive serum test at screening for an active infection: , ,
  • Current or history (ie, within 12 months of screening) of alcohol, drug, or medication abuse as assessed by the investigator
  • Pregnant or lactating females and those who intend to become pregnant during the study
  • Live or received \<4 weeks before baseline visit

The full list of exclusion criteria can be found in the protocol.

Terms in these criteria, in plain language(14)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Live vaccines

Vaccines made with a weakened form of the germ, such as measles–mumps–rubella (MMR), chickenpox and yellow fever. They can be risky when the immune system is weakened. Flu injections are not live; the nasal flu spray is.

05

Study design

Phase
Phase 2 / Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
98 participants (actual)

Study arms

  • Experimental
    efgartigimod PH20 SC

    participants receiving efgartigimod PH20 SC on top of Prednisone

    Biological: efgartigimod PH20 SC · Drug: Prednisone

  • Placebo comparator
    placebo PH20 SC

    participants receiving placebo PH20 SC on top of Prednisone

    Other: placebo · Drug: Prednisone

Interventions

  • Biologicalefgartigimod PH20 SC

    Drug pages: Efgartigimod alfa · Hyaluronidase (human recombinant)

    Subcutaneous injection of efgartigimod coformulated with rHuPH20, a permeation enhancer

  • Otherplacebo

    Subcutaneous injection of placebo coformulated with rHuPH20, a permeation enhancer

  • Oral Prednisone

06

What researchers measure

Primary outcomes

  1. Number of Participants With CRoff at Week 36

    CRoff = complete remission while receiving efgartigimod PH20 SC or placebo and being off oral corticosteroid therapy for at least 8 weeks. Complete remission is defined as the absence of new lesions, complete healing of existing lesions and absence of pruritus.

    Time frame: at week 36

Secondary outcomes

  1. Cumulative OCS Dose

    OCS = oral corticosteroid

    Time frame: up to week 36

  2. Number of Participants Who Achieve an IGA-BP Score of 0 While Off OCS Therapy for ≥8 Weeks at Week 36

    IGA-BP = Investigator Global Assessment of Bullous Pemphigoid. IGA-BP scores range from 0-4, with a higher score representing severe BP. OCS = oral corticosteroid

    Time frame: at week 36

  3. Number of Participants With CDA Who Remained Free of Relapse Through Week 36

    Control of disease activity (CDA) is defined as the point at which new lesions ceased to form, established lesions began to heal, and pruritic symptoms started to abate. Relapse is defined as the appearance of 3 or more new lesions a month or at least 1 large lesion that did not heal within 1 week, or extension of established lesions or daily pruritus in a participant who had achieved CDA.

    Time frame: up to week 36

  4. Number of Participants With CRmin at Week 36

    CRmin = complete remission receiving minimal oral corticosteroids for at least 8 weeks. Minimal oral corticosteroid (OCS) therapy is defined as ≤0.1 mg/kg/day of prednisone (or equivalent).

    Time frame: at week 36

  5. Change From Baseline to Week 36 in the 24-Hour Average Itch NRS Score

    Itch NRS = Itch Numerical Rating Scale. The Itch NRS scores range from 0-10 with 10 representing the worst imaginable itch.

    Time frame: up to week 36

  6. Changes From Baseline in the BPDAI Total Activity Score

    BPDAI = Bullous Pemphigoid Disease Area Index (BPDAI) Total Activity Score is a tool to objectively measure disease activity. BPDAI scores range from 0 to 360 with a higher score indicating more severe disease (max 240 for total skin activity and 120 for mucosal activity).

    Time frame: up to week 36

  7. Time to CDA

    CDA = control of disease activity, the point at which new lesions ceased to form, established lesions began to heal, and pruritic symptoms started to abate.

    Time frame: up to week 36

  8. Time to CR

    CR = complete remission, the absence of new lesions, complete healing of existing lesions, and absence of pruritus.

    Time frame: up to week 36

  9. Time to CRmin

    CRmin = complete remission, the absence of new lesions, complete healing of existing lesions, and absence of pruritus while being on minimal dose of OCS for ≥8 Weeks. OCS = oral corticosteroid. Minimal OCS therapy is defined as an oral prednisone dosage of ≤0.10 mg/kg/day (or equivalent).

    Time frame: up to week 36

  10. Time to CRoff/PRoff

    CRoff= complete remission (the absence of new lesions, complete healing of existing lesions, and absence of pruritus) while receiving efgartigimod PH20 SC or placebo and being off oral corticosteroid therapy for at least 8 weeks. PRoff = partial remission (the presence of only new transient lesions) while receiving efgartigimod PH20 SC or placebo and being off oral corticosteroid therapy for at least 8 weeks.

    Time frame: up to week 36

  11. Time to CRoff

    CRoff is defined as the absence of new lesions, complete healing of existing lesions, and absence of pruritus while being off OCS therapy for ≥8 weeks.

    Time frame: up to week 36

  12. Time From CDA to Achieve Relapse

    CDA is defined as the point at which new lesions ceased to form, established lesions began to heal, and pruritic symptoms started to abate. Relapse is defined as the appearance of 3 or more new lesions a month or at least 1 large lesion that did not heal within 1 week, or extension of established lesions or daily pruritus in a participant who had achieved CDA.

    Time frame: up to week 36

  13. Number of Participants Who Receive Rescue Therapy Before Week 36

    Time frame: at week 36

  14. The AIS From the GTI

    The Aggregate Improvement Score (AIS) from the Glucocorticoid Toxicity Index (GTI) can range from -346 to 439 with a higher score representing greater corticosteroid toxicity. If a study drug is effective at lowering greater corticosteroid toxicity over time, the score will be lower.

    Time frame: up to week 36

  15. The CWS From the GTI

    The Cumulative Worsening Score (CWS) from the Glucocorticoid Toxicity Index (GTI) can range from 0 to 439 with a higher score representing greater corticosteroid toxicity.

    Time frame: up to week 36

  16. EQ-5D-5L VAS Scores Over Time

    The EuroQol 5-Dimension 5-Level Visual Analog Scale (EQ-5D-5L VAS) scores range from 0-100 with 0 representing the worst health.

    Time frame: up to week 36

  17. DLQI Scores Over Time

    Dermatology Life Quality Index (DLQI) assess the participant's perception of the impact of skin diseases on different aspects of their health-related QoL. Scores range from 0 to 30 with a higher score representing a worse quality of life.

    Time frame: up to week 36

  18. ABQoL Scores Over Time

    Autoimmune Bullous Disease Quality of Life Index (ABQoL) questionnaire assesses the impact of Autoimmune Bullous Disease and their therapies on the daily life of patients. Scores range from 0 to 51 with a higher score representing a worse quality of life.

    Time frame: up to week 36

  19. Efgartigimod Serum Concentrations

    Time frame: up to week 36

  20. Percent Change of Total IgG Serum Levels From Baseline Over Time

    Time frame: up to 36 weeks

  21. Percent Change of Anti-BP180 and Anti-BP230 Antibodies From Baseline Over Time

    Time frame: up to 36 weeks

  22. Incidence of Antidrug Antibodies Against Efgartigimod and Antibodies Produced Against rHuPH20

    Time frame: up to 46 weeks

  23. Number of Participants (or Their Caregivers) Who Are Determined by Site Staff to be Sufficiently Competent in (Self-)Administering Efgartigimod PH20 SC

    Time frame: up to week 32

07

Results

Posted Oct 23, 2025

Participant flow

Participant flow — Overall Study
MilestoneEfgartigimod PH20 SCPlacebo PH20 SC
Started5048
Completed3535
Not completed1513
Withdrew: Adverse event14
Withdrew: Death12
Withdrew: Lack of efficacy12
Withdrew: Lost to follow-up30
Withdrew: Physician decision40
Withdrew: Treatment unblinded01
Withdrew: Withdrawal by subject54

Outcome measures

PrimaryNumber of Participants With CRoff at Week 36

CRoff = complete remission while receiving efgartigimod PH20 SC or placebo and being off oral corticosteroid therapy for at least 8 weeks. Complete remission is defined as the absence of new lesions, complete healing of existing lesions and absence of pruritus.

Time frame:
at week 36
Reported as:
Count of participants · Participants
Number of Participants With CRoff at Week 36
ParticipantsEfgartigimod PH20 SCPlacebo PH20 SC
Number of Participants With CRoff at Week 3682
SecondaryCumulative OCS Dose

OCS = oral corticosteroid

Time frame:
up to week 36
Reported as:
Mean · mg/kg/day
Cumulative OCS Dose
mg/kg/dayEfgartigimod PH20 SCPlacebo PH20 SC
Cumulative OCS Dose0.242 ± 0.1380.289 ± 0.173
SecondaryNumber of Participants Who Achieve an IGA-BP Score of 0 While Off OCS Therapy for ≥8 Weeks at Week 36

IGA-BP = Investigator Global Assessment of Bullous Pemphigoid. IGA-BP scores range from 0-4, with a higher score representing severe BP. OCS = oral corticosteroid

Time frame:
at week 36
Reported as:
Count of participants · Participants
Number of Participants Who Achieve an IGA-BP Score of 0 While Off OCS Therapy for ≥8 Weeks at Week 36
ParticipantsEfgartigimod PH20 SCPlacebo PH20 SC
Number of Participants Who Achieve an IGA-BP Score of 0 While Off OCS Therapy for ≥8 Weeks at Week 3693
SecondaryNumber of Participants With CDA Who Remained Free of Relapse Through Week 36

Control of disease activity (CDA) is defined as the point at which new lesions ceased to form, established lesions began to heal, and pruritic symptoms started to abate. Relapse is defined as the appearance of 3 or more new lesions a month or at least 1 large lesion that did not heal within 1 week, or extension of established lesions or daily pruritus in a participant who had achieved CDA.

Time frame:
up to week 36
Reported as:
Count of participants · Participants
Number of Participants With CDA Who Remained Free of Relapse Through Week 36
ParticipantsEfgartigimod PH20 SCPlacebo PH20 SC
Number of Participants With CDA Who Remained Free of Relapse Through Week 3678
SecondaryNumber of Participants With CRmin at Week 36

CRmin = complete remission receiving minimal oral corticosteroids for at least 8 weeks. Minimal oral corticosteroid (OCS) therapy is defined as ≤0.1 mg/kg/day of prednisone (or equivalent).

Time frame:
at week 36
Reported as:
Count of participants · Participants
Number of Participants With CRmin at Week 36
ParticipantsEfgartigimod PH20 SCPlacebo PH20 SC
Number of Participants With CRmin at Week 3683
SecondaryChange From Baseline to Week 36 in the 24-Hour Average Itch NRS Score

Itch NRS = Itch Numerical Rating Scale. The Itch NRS scores range from 0-10 with 10 representing the worst imaginable itch.

Time frame:
up to week 36
Reported as:
Mean · score on a scale
Change From Baseline to Week 36 in the 24-Hour Average Itch NRS Score
score on a scaleEfgartigimod PH20 SCPlacebo PH20 SC
Change From Baseline to Week 36 in the 24-Hour Average Itch NRS Score-4.4 ± 3.35-2.4 ± 4.26
SecondaryChanges From Baseline in the BPDAI Total Activity Score

BPDAI = Bullous Pemphigoid Disease Area Index (BPDAI) Total Activity Score is a tool to objectively measure disease activity. BPDAI scores range from 0 to 360 with a higher score indicating more severe disease (max 240 for total skin activity and 120 for mucosal activity).

Time frame:
up to week 36
Reported as:
Mean · score on a scale
Changes From Baseline in the BPDAI Total Activity Score
score on a scaleEfgartigimod PH20 SCPlacebo PH20 SC
Changes From Baseline in the BPDAI Total Activity Score-43.13 ± 19.633-43.56 ± 32.584
SecondaryTime to CDA

CDA = control of disease activity, the point at which new lesions ceased to form, established lesions began to heal, and pruritic symptoms started to abate.

Time frame:
up to week 36
Reported as:
Median · days
Time to CDA
daysEfgartigimod PH20 SCPlacebo PH20 SC
Time to CDA16.0 (10.0 to 17.0)15.0 (13.0 to 22.0)
SecondaryTime to CR

CR = complete remission, the absence of new lesions, complete healing of existing lesions, and absence of pruritus.

Time frame:
up to week 36
Reported as:
Median · days
Time to CR
daysEfgartigimod PH20 SCPlacebo PH20 SC
Time to CR134.0 (85.0 to NA)99.0 (57.0 to 225.0)
SecondaryTime to CRmin

CRmin = complete remission, the absence of new lesions, complete healing of existing lesions, and absence of pruritus while being on minimal dose of OCS for ≥8 Weeks. OCS = oral corticosteroid. Minimal OCS therapy is defined as an oral prednisone dosage of ≤0.10 mg/kg/day (or equivalent).

Time frame:
up to week 36
Reported as:
Median · days
Time to CRmin
daysEfgartigimod PH20 SCPlacebo PH20 SC
Time to CRminNA (247.0 to NA)NA (NA to NA)
SecondaryTime to CRoff/PRoff

CRoff= complete remission (the absence of new lesions, complete healing of existing lesions, and absence of pruritus) while receiving efgartigimod PH20 SC or placebo and being off oral corticosteroid therapy for at least 8 weeks. PRoff = partial remission (the presence of only new transient lesions) while receiving efgartigimod PH20 SC or placebo and being off oral corticosteroid therapy for at least 8 weeks.

Time frame:
up to week 36
Reported as:
Median · days
Time to CRoff/PRoff
daysEfgartigimod PH20 SCPlacebo PH20 SC
Time to CRoff/PRoffNA (NA to NA)NA (NA to NA)
SecondaryTime to CRoff

CRoff is defined as the absence of new lesions, complete healing of existing lesions, and absence of pruritus while being off OCS therapy for ≥8 weeks.

Time frame:
up to week 36
Reported as:
Median · days
Time to CRoff
daysEfgartigimod PH20 SCPlacebo PH20 SC
Time to CRoffNA (NA to NA)NA (NA to NA)
SecondaryTime From CDA to Achieve Relapse

CDA is defined as the point at which new lesions ceased to form, established lesions began to heal, and pruritic symptoms started to abate. Relapse is defined as the appearance of 3 or more new lesions a month or at least 1 large lesion that did not heal within 1 week, or extension of established lesions or daily pruritus in a participant who had achieved CDA.

Time frame:
up to week 36
Reported as:
Median · days
Time From CDA to Achieve Relapse
daysEfgartigimod PH20 SCPlacebo PH20 SC
Time From CDA to Achieve Relapse114.0 (78.0 to 160.0)105.0 (71.0 to 163.0)
SecondaryNumber of Participants Who Receive Rescue Therapy Before Week 36
Time frame:
at week 36
Reported as:
Count of participants · Participants
Number of Participants Who Receive Rescue Therapy Before Week 36
ParticipantsEfgartigimod PH20 SCPlacebo PH20 SC
Number of Participants Who Receive Rescue Therapy Before Week 361918
SecondaryThe AIS From the GTI

The Aggregate Improvement Score (AIS) from the Glucocorticoid Toxicity Index (GTI) can range from -346 to 439 with a higher score representing greater corticosteroid toxicity. If a study drug is effective at lowering greater corticosteroid toxicity over time, the score will be lower.

Time frame:
up to week 36
Reported as:
Mean · score on a scale
The AIS From the GTI
score on a scaleEfgartigimod PH20 SCPlacebo PH20 SC
The AIS From the GTI5.7 ± 56.9810.9 ± 45.42
SecondaryThe CWS From the GTI

The Cumulative Worsening Score (CWS) from the Glucocorticoid Toxicity Index (GTI) can range from 0 to 439 with a higher score representing greater corticosteroid toxicity.

Time frame:
up to week 36
Reported as:
Mean · score on a scale
The CWS From the GTI
score on a scaleEfgartigimod PH20 SCPlacebo PH20 SC
The CWS From the GTI56.1 ± 40.7147.5 ± 46.68
SecondaryEQ-5D-5L VAS Scores Over Time

The EuroQol 5-Dimension 5-Level Visual Analog Scale (EQ-5D-5L VAS) scores range from 0-100 with 0 representing the worst health.

Time frame:
up to week 36
Reported as:
Mean · score on a scale
EQ-5D-5L VAS Scores Over Time
score on a scaleEfgartigimod PH20 SCPlacebo PH20 SC
EQ-5D-5L VAS Scores Over Time12.7 ± 15.944.5 ± 24.44
SecondaryDLQI Scores Over Time

Dermatology Life Quality Index (DLQI) assess the participant's perception of the impact of skin diseases on different aspects of their health-related QoL. Scores range from 0 to 30 with a higher score representing a worse quality of life.

Time frame:
up to week 36
Reported as:
Mean · score on a scale
DLQI Scores Over Time
score on a scaleEfgartigimod PH20 SCPlacebo PH20 SC
DLQI Scores Over Time-7.3 ± 6.25-6.7 ± 7.14
SecondaryABQoL Scores Over Time

Autoimmune Bullous Disease Quality of Life Index (ABQoL) questionnaire assesses the impact of Autoimmune Bullous Disease and their therapies on the daily life of patients. Scores range from 0 to 51 with a higher score representing a worse quality of life.

Time frame:
up to week 36
Reported as:
Mean · score on a scale
ABQoL Scores Over Time
score on a scaleEfgartigimod PH20 SCPlacebo PH20 SC
ABQoL Scores Over Time-12.3 ± 6.44-12.0 ± 10.92
SecondaryEfgartigimod Serum Concentrations
Time frame:
up to week 36
Reported as:
Mean · ug/mL
Efgartigimod Serum Concentrations
ug/mLEfgartigimod PH20 SC
Week 135.7 ± 13.6
Day 1096.4 ± 23.9
Week 237.3 ± 12.5
Week 426.0 ± 11.0
Week 825.8 ± 10.5
Week 1224.4 ± 8.92
Week 1624.3 ± 8.51
Week 2023.9 ± 9.12
Week 2424.3 ± 9.98
Week 2624.6 ± 10.2
Week 2823.3 ± 10.3
Week 3226.1 ± 11.3
Week 3622.2 ± 8.59
SecondaryPercent Change of Total IgG Serum Levels From Baseline Over Time
Time frame:
up to 36 weeks
Reported as:
Mean · percent change
Percent Change of Total IgG Serum Levels From Baseline Over Time
percent changeEfgartigimod PH20 SCPlacebo PH20 SC
Percent Change of Total IgG Serum Levels From Baseline Over Time-46.91 ± 42.244-7.65 ± 25.374
SecondaryPercent Change of Anti-BP180 and Anti-BP230 Antibodies From Baseline Over Time
Time frame:
up to 36 weeks
Reported as:
Mean · Percent change in RU/mL
Percent Change of Anti-BP180 and Anti-BP230 Antibodies From Baseline Over Time
Percent change in RU/mLEfgartigimod PH20 SCPlacebo PH20 SC
Percent change of Anti-BP180 antibodies from baseline over time-58.58 ± 56.983-57.98 ± 33.470
Percent change of Anti-BP230 antibodies from baseline over time-46.72 ± 35.950-50.95 ± 28.617
SecondaryIncidence of Antidrug Antibodies Against Efgartigimod and Antibodies Produced Against rHuPH20
Time frame:
up to 46 weeks
Reported as:
Count of participants · Participants
Incidence of Antidrug Antibodies Against Efgartigimod and Antibodies Produced Against rHuPH20
ParticipantsEfgartigimod PH20 SCPlacebo PH20 SC
ADA against efgartigimod22
Antibodies against rHuPH2090
SecondaryNumber of Participants (or Their Caregivers) Who Are Determined by Site Staff to be Sufficiently Competent in (Self-)Administering Efgartigimod PH20 SC
Time frame:
up to week 32
Reported as:
Count of participants · Participants
Number of Participants (or Their Caregivers) Who Are Determined by Site Staff to be Sufficiently Competent in (Self-)Administering Efgartigimod PH20 SC
ParticipantsEfgartigimod PH20 SCPlacebo PH20 SC
Participants54
Caregivers23

Adverse events

Collected over up to 46 weeks. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Efgartigimod PH20 SC1/50 (2%)12/50 (24%)47/50 (94%)
Placebo PH20 SC2/48 (4.2%)12/48 (25%)46/48 (95.8%)
Most frequent serious events
Showing 10 of 43
Most frequent serious events
EventEfgartigimod PH20 SCPlacebo PH20 SC
DEEP VEIN THROMBOSISVascular disorders0/502/48
CONDITION AGGRAVATEDGeneral disorders2/500/48
PNEUMONIAInfections and infestations2/500/48
ACUTE MYOCARDIAL INFARCTIONCardiac disorders0/501/48
ATRIAL FIBRILLATIONCardiac disorders1/501/48
CARDIAC FAILURECardiac disorders0/501/48
CORONARY ARTERY STENOSISCardiac disorders0/501/48
SINUS NODE DYSFUNCTIONCardiac disorders0/501/48
CUSHING'S SYNDROMEEndocrine disorders0/501/48
NON-CARDIAC CHEST PAINGeneral disorders0/501/48
Most frequent other events
Showing 10 of 41
Most frequent other events
EventEfgartigimod PH20 SCPlacebo PH20 SC
INSOMNIAPsychiatric disorders7/508/48
INCREASED TENDENCY TO BRUISEBlood and lymphatic system disorders5/507/48
HEADACHENervous system disorders7/502/48
URINARY TRACT INFECTIONInfections and infestations5/506/48
COUGHRespiratory, thoracic and mediastinal disorders6/500/48
HYPERTENSIONVascular disorders6/502/48
OEDEMA PERIPHERALGeneral disorders5/505/48
BACK PAINMusculoskeletal and connective tissue disorders5/505/48
PRURITUSSkin and subcutaneous tissue disorders4/505/48
LYMPHOPENIABlood and lymphatic system disorders5/503/48

Baseline characteristics

Age, Continuous
Age, Continuous(years)Efgartigimod PH20 SCPlacebo PH20 SCTotal
Mean71.0 ± 12.0270.9 ± 9.3770.9 ± 10.75
Age, Customized
Age, Customized(Participants)Efgartigimod PH20 SCPlacebo PH20 SCTotal
18 - <65 years121123
65 - <75 years181735
75 - <85 years151732
>=85 years538
Sex: Female, Male
Sex: Female, Male(Participants)Efgartigimod PH20 SCPlacebo PH20 SCTotal
Female373572
Male131326
Race/Ethnicity, Customized
Race/Ethnicity, Customized(Participants)Efgartigimod PH20 SCPlacebo PH20 SCTotal
AMERICAN INDIAN OR ALASKA NATIVE101
ASIAN8917
MULTIPLE101
WHITE403979
Race/Ethnicity, Customized
Race/Ethnicity, Customized(Participants)Efgartigimod PH20 SCPlacebo PH20 SCTotal
HISPANIC OR LATINO101
NOT HISPANIC OR LATINO494897
08

Study locations

129 sites
  • Investigator site 74 - US0010178
    Phoenix, Arizona 85006, United States
  • Investigator site 6 - US0010138
    Fountain Valley, California 92708, United States
  • Investigator site 121 - US0010092
    Redwood City, California 94063, United States
  • Investigator site 72 - US0010186
    Santa Monica, California 90404, United States
  • Investigator site 10 - US0010153
    Castle Rock, Colorado 80109, United States
  • Investigator site 2 - US0010087
    Boca Raton, Florida 33428, United States
  • Investigator site 21 - US0010152
    Clearwater, Florida 33756, United States
  • Investigator site 1 - US0010017
    Miami, Florida 33173, United States
  • Investigator site 13 - US0010155
    West Lafayette, Indiana 47906, United States
  • Investigator site 35 - US0010156
    Louisville, Kentucky 40217, United States
  • Investigator site 50 - US0010149
    Ann Arbor, Michigan 48109, United States
  • Investigator site 115 - US0010157
    Jackson, Mississippi 39216, United States
  • Investigator site 73 - US0010098
    St Louis, Missouri 63110, United States
  • Investigator site 85 - US0010159
    Lebanon, New Hampshire 03756, United States
  • Investigator site 5 - US0010088
    Buffalo, New York 14203, United States
  • Investigator site 93 - US0010169
    New York, New York 10016, United States
  • Investigator site 4 - US0010137
    Fairborn, Ohio 45324, United States
  • Investigator site 25 - US0010158
    Pittsburgh, Pennsylvania 15213, United States
  • Investigator site 34 - US0010182
    Houston, Texas 77004, United States
  • Investigator site 92 - US0010150
    Murray, Utah 84107, United States
  • Investigator site 3 - US0010151
    Morgantown, West Virginia 26505, United States
  • Investigator site 36 - AU0610013
    Fitzroy, 3065, Australia
  • Investigator site 27 - AU0610006
    Kogarah, 2217, Australia
  • Investigator site 125 - AU0610019
    Woolloongabba, 4102, Australia
  • Investigator site 28 - BG3590018
    Sofia, 1407, Bulgaria
  • Investigator site 14 - BG3590010
    Sofia, 1431, Bulgaria
  • Investigator site 15 - BG3590020
    Stara Zagora, 6003, Bulgaria
  • Investigator site 111 - CN0860064
    Beijing, 100006, China
  • Investigator site 91 - CN0860017
    Beijing, China
  • Investigator site 95 - CN0860018
    Chengdu, China
  • Investigator site 116 - CN0860027
    Chongqing, 400016, China
  • Investigator site 108 - CN0860023
    Fujian, 350004, China
  • Investigator site 107 - CN0860021
    Guangzhou, 510091, China
  • Investigator site 110 - CN0860053
    Guanzhou, 510080, China
  • Investigator site 128 - CN0860097
    Hefei, China
  • Investigator site 124 - CN0860098
    Nanchang, 330000, China
  • Investigator site 94 - CN0860066
    Nanyang, China
  • Investigator site 127 - CN860020
    Shanghai, 200025, China
  • Investigator site 123 - CN0860095
    Shanghai, 200435, China
  • Investigator site 122 - CN0860065
    Ürümqi, 830054, China
  • Investigator site 109 - CN0860025
    Wuhan, 430031, China
  • Investigator site 126 - CN0860026
    Zhengzhou, 450003, China
  • Investigator site 22 - HR3850003
    Split, 21000, Croatia
  • Investigator site 16 - HR3850002
    Zagreb, 10000, Croatia
  • Investigator site 37 - HR3850001
    Zagreb, 10000, Croatia
  • Investigator site 97 - CZ4200015
    Brno, 656 91, Czechia
  • Investigator site 118 - CZ4200016
    Hradec Králové, 500 05, Czechia
  • Investigator site 117 - CZ4200013
    Plzen-Bory, 13, 301 00, Czechia
  • Investigator site 96 - CZ4200012
    Prague, 180 81, Czechia
  • Investigator site 38 - FR0330040
    Nice, 06202, France
  • Investigator site 29 - FR0330029
    Rouen, 76031, France
  • Investigator site 46 - DE0490039
    Berlin, 10117, Germany
  • Investigator site 54 - DE0490030
    Dresden, 01307, Germany
  • Investigator site 80 - DE0490041
    Düsseldorf, 40225, Germany
  • Investigator site 57 - DE0490046
    Erlangen, 91054, Germany
  • Investigator site 51 - DE0490008
    Essen, 45147, Germany
  • Investigator site 52 - DE0490024
    Frankfurt am Main, 60590, Germany
  • Investigator site 53 - DE0490023
    Freiburg im Breisgau, 79104, Germany
  • Investigator site 56 - DE0490028
    Kiel, 24105, Germany
  • Investigator site 45 - DE0490001
    Marburg, 35043, Germany
  • Investigator site 75 - DE0490047
    München, 85006, Germany
  • Investigator site 55 - DE0490026
    Würzburg, 97080, Germany
  • Investigator site 60 - GE0300004
    Athens, 11525, Greece
  • Investigator site 62 - GE0300006
    Athens, 11525, Greece
  • Investigator site 58 - GR0300001
    Athens, 16121, Greece
  • Investigator site 76 - GR030003
    Chaïdári, 12462, Greece
  • Investigator site 61 - GE0300002
    Thessaloniki, 54643, Greece
  • Investigator site 59 - GR0300005
    Thessaloniki, 56429, Greece
  • Investigator site 26 - HU0360023
    Budapest, 1085, Hungary
  • Investigator site 11 - HU0360003
    Debrecen, 4032, Hungary
  • Investigator site 7 - HU0360008
    Pécs, 7632, Hungary
  • Investigator site 39 - IL9720003
    Afula, 1834111, Israel
  • Investigator site 63 - IL9720018
    Haifa, 3109601, Israel
  • Investigator site 41 - IL9720001
    Ramat Gan, 5262100, Israel
  • Investigator site 40 - IL9720002
    Tel Aviv, 64239, Israel
  • Investigator site 65 - IT0390055
    Bologna, 40138, Italy
  • Investigator site 43 - IT0390060
    Brescia, 25132, Italy
  • Investigator site 78 - IT0390039
    Catania, 95123, Italy
  • Investigator site 47 - IT0390031
    Florence, 50122, Italy
  • Investigator site 86 - IT0390067
    Florence, 50122, Italy
  • Investigator site 81 - IT0390030
    Genova, 16132, Italy
  • Investigator site 77 - IT0390062
    Milan, 20122, Italy
  • Investigator site 119 - IT0390066
    Parma, 43126, Italy
  • Investigator site 64 - IT0390061
    Pavia, 27100, Italy
  • Investigator site 23 - IT0390006
    Roma, 00167, Italy
  • Investigator site 42 - IT0390005
    Roma, 00168, Italy
  • Investigator site 30 - IT0390040
    Siena, 53100, Italy
  • Investigator site 103 - JP0810070
    Kumamoto, 860-8556, Japan
  • Investigator site 99 - JP0810050
    Kurume, 830-0011, Japan
  • Investigator site 104 - JP0810071
    Maebashi, 371-8511, Japan
  • Investigator site 100 - JP0810046
    Nagakute, 480-1195, Japan
  • Investigator site 129 - JP0810073
    Niigata, 951-8520, Japan
  • Investigator site 101 - JP0810049
    Osaka, 545-8586, Japan
  • Investigator site 102 - JP0810069
    Ōsaka-sayama, 589-8511, Japan
  • Investigator site 112 - JP0810045
    Sapporo, 060-8648, Japan
  • Investigator site 105 - JP0810067
    Sendai, 980-8574, Japan
  • Investigator site 98 - JP0810043
    Tokyo, 113-8431, Japan
  • Investigator site 106 - JP0810068
    Yokohama, 236-0004, Japan
  • Investigator site 87 - LV3710005
    Riga, 1001, Latvia
  • Investigator site 82 - LV3710003
    Riga, 1003, Latvia

Showing the first 100 of 129 sites across 21 countries. Choose a country and city above to see the rest.

09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Jun 2022 to primary completion in Sep 2024, 27 months.

Results were first posted in Oct 2025, 1 year 1 month after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Feb 14, 2022
First posted
Mar 4, 2022
StartActual
Jun 9, 2022
Primary completionActual
Sep 13, 2024
CompletionActual
Sep 13, 2024
Results first posted
Oct 23, 2025
Last update
Oct 23, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Oct 23, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT05267600
Lead sponsor
argenx
Responsible party
Sponsor
First posted
Mar 4, 2022
Start date
Jun 9, 2022
Primary completion
Sep 13, 2024
Completion
Sep 13, 2024
Results posted
Oct 23, 2025
Last update
Oct 23, 2025

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Sep 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Efgartigimod alfa · Hyaluronidase (human recombinant)

Start the discussion